Trial Information
B-CLL Subgroups: Maturation Stage and Gene Expression
Inclusion Criteria:
- 18 years of age,
- Patients must be able to contribute the required amount of blood without compromising
their well being,
- Participants must be willing to be contacted again in the future for additional blood
drawing.
Exclusion Criteria:
- Patients who are known to be anemic, with a hemoglobin < 8,
- Patients who are known to be infected with HIV.
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Cross-Sectional
Outcome Measure:
differentiating B-CLL cells by the presence or absence of mutations in antibody genes and/or by the percentage of cells expressing CD38 and the differnce in clinical disease course and outcome for each group
Outcome Time Frame:
follow through the clinical disease course for each group
Safety Issue:
No
Principal Investigator
Nicholas Chiorazzi, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
North Shore-LIJ Health System
Authority:
United States: Institutional Review Board
Study ID:
04-057
NCT ID:
NCT01030913
Start Date:
December 1999
Completion Date:
January 2015
Related Keywords:
- Chronic Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
Name | Location |
Feinstein Institute for Medical Research |
Manhassett, New York 11030 |